337 related articles for article (PubMed ID: 31436896)
1. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
Vondrak K; Parisi F; Dhawan A; Grenda R; Webb NJA; Marks SD; Debray D; Holt RCL; Lachaux A; Kelly D; Kazeem G; Undre N
Clin Transplant; 2019 Oct; 33(10):e13698. PubMed ID: 31436896
[TBL] [Abstract][Full Text] [Related]
2. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
Shin MH; Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Yun YI; Kim WJ; Kang WH; Kim SH; Jiang H; Lee S; Tak EY
Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.
Rubik J; Debray D; Kelly D; Iserin F; Webb NJA; Czubkowski P; Vondrak K; Sellier-Leclerc AL; Rivet C; Riva S; Tönshoff B; D'Antiga L; Marks SD; Reding R; Kazeem G; Undre N
Transpl Int; 2019 Nov; 32(11):1182-1193. PubMed ID: 31325368
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
[TBL] [Abstract][Full Text] [Related]
5. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study.
TruneČka P; Klempnauer J; Bechstein WO; Pirenne J; Friman S; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Tisone G;
Am J Transplant; 2015 Jul; 15(7):1843-54. PubMed ID: 25707487
[TBL] [Abstract][Full Text] [Related]
6. Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization.
Ho B; Bhagat H; Schwartz JJ; Atiemo K; Daud A; Kang R; Montag SE; Zhao L; Lee E; Skaro AI; Ladner DP
Adv Ther; 2019 Jun; 36(6):1465-1479. PubMed ID: 30941724
[TBL] [Abstract][Full Text] [Related]
7. Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience.
Turunc V; Ari E; Guven B; Tabendeh B; Yildiz A
Transplant Proc; 2019 Sep; 51(7):2308-2311. PubMed ID: 31400977
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
Wakasugi N; Uchida H; Uno S
Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy.
Ericzon BG; Varo E; Trunečka P; Fischer L; Colledan M; Gridelli B; Valdivieso A; O'Grady J; Dickinson J; Undre N
Clin Transplant; 2017 Jun; 31(6):. PubMed ID: 28295581
[TBL] [Abstract][Full Text] [Related]
10. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
11. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
12. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics of tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus to prolonged-release tacrolimus formulation.
Rubik J; Debray D; Iserin F; Vondrak K; Sellier-Leclerc AL; Kelly D; Czubkowski P; Webb NJA; Riva S; D'Antiga L; Marks SD; Rivet C; Tönshoff B; Kazeem G; Undre N
Pediatr Transplant; 2019 Jun; 23(4):e13391. PubMed ID: 30932313
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
[TBL] [Abstract][Full Text] [Related]
15. Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study.
Adam R; Karam V; Cailliez V; Trunečka P; Samuel D; Tisone G; Němec P; Soubrane O; Schneeberger S; Gridelli B; Bechstein WO; Risaliti A; Line PD; Vivarelli M; Rossi M; Pirenne J; Klempnauer JL; Rummo A; Di Benedetto F; Zieniewicz K; Troisi R; Paul A; Vali T; Kollmar O; Boudjema K; Hoti E; Colledan M; Pratschke J; Lang H; Popescu I; Ericzon BG; Strupas K; De Simone P; Kochs E; Heyd B; Gugenheim J; Pinna AD; Bennet W; Kazimi M; Bachellier P; Wigmore SJ; Rasmussen A; Clavien PA; Hidalgo E; O'Grady JG; Zamboni F; Kilic M; Duvoux C;
Transplantation; 2019 Sep; 103(9):1844-1862. PubMed ID: 31343568
[TBL] [Abstract][Full Text] [Related]
16. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
[TBL] [Abstract][Full Text] [Related]
17. Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients.
Rummo O; Carmellini M; Kamar N; Durrbach A; Mousson C; Caputo F; Mathe Z; Christiaans MHL; Kuypers DRJ; Klempnauer J; Anaokar S; Hurst M; Kazeem G; Undre N; Lehner F
Transpl Int; 2020 Feb; 33(2):161-173. PubMed ID: 31536654
[TBL] [Abstract][Full Text] [Related]
18. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values.
Leino AD; King EC; Jiang W; Vinks AA; Klawitter J; Christians U; Woodle ES; Alloway RR; Rohan JM
Am J Transplant; 2019 May; 19(5):1410-1420. PubMed ID: 30506623
[TBL] [Abstract][Full Text] [Related]
19. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
Muduma G; Odeyemi I; Pollock RF
J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
